Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.04% is 31% below its 5-year average of 1.51%, around the middle of its 5-year range (0.07%–1.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.57% below its 12-month average of 1.42%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.04%.
DEBT TO ASSETS RATIO
1.04%
DEBT TO ASSETS RATIO AVG TTM
1.42%
DEBT TO ASSETS RATIO AVG 3Y
1.18%
DEBT TO ASSETS RATIO AVG 5Y
1.51%
DEBT TO ASSETS RATIO AVG 10Y
1.03%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-26.57%
CURRENT VS 3Y AVG
-11.96%
CURRENT VS 5Y AVG
-31.05%
CURRENT VS 10Y AVG
+1.49%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+1056.35%
vs the sector median at left
Protagonist Therapeutics, Inc.
Market Cap
$8.83B
Debt to Assets Ratio
1.04%
TTM Avg
1.42%
3Y Avg
1.18%
5Y Avg
1.51%
Market Cap
$8.73B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.00B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$8.61B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.83B | 1.04% | 1.42% | 1.18% | 1.51% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.73B | 0.41% | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $8.98B | 0.32% | N/A | N/A | N/A |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.00B | 0.29% | N/A | N/A | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.61B | 0.05% | N/A | N/A | N/A |
| Bruker Corporation (BRKR)vs › | $9.26B | 0.32% | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.34B | 0.04% | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.38B | 0.30% | N/A | N/A | N/A |
| Vaxcyte, Inc. (PCVX)vs › | $9.38B | 0.04% | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.61B | 0.01% | N/A | N/A | N/A |
Debt/Assets
1.0%
Debt/Equity
0.01
Current Ratio
21.71
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.04% |
| 2026-03-31 | 1.40% |
| 2025-12-31 | 1.54% |
| 2025-09-30 | 1.53% |
| 2025-06-30 | 1.57% |
| 2025-03-31 | 1.53% |
| 2024-12-31 | 1.46% |
| 2024-09-30 | 1.81% |
| 2024-06-30 | 1.78% |
| 2024-03-31 | 0.07% |
| 2023-12-31 | 0.32% |
| 2023-09-30 | 0.55% |
| 2023-06-30 | 0.76% |
| 2023-03-31 | 1.28% |
| 2022-12-31 | 1.47% |
| 2022-09-30 | 1.50% |
| 2022-06-30 | 1.55% |
| 2022-03-31 | 1.53% |
| 2021-12-31 | 1.68% |
| 2021-09-30 | 1.68% |
| 2021-06-30 | 1.30% |
| 2021-03-31 | 1.88% |
| 2020-12-31 | 1.84% |
| 2020-09-30 | 2.89% |
| 2020-06-30 | 2.94% |
| 2020-03-31 | 12.42% |
| 2019-12-31 | 10.98% |
| 2019-09-30 | 4.85% |
| 2019-06-30 | 5.25% |
| 2019-03-31 | 6.08% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
